California attorney general sues PBMs, drugmakers for boosting insulin prices

California’s attorney general filed suit against three pharmacy benefit managers and three drugmakers Jan. 12 with the accusation of “aggressively hiking” the price of insulin. 

Advertisement

The lawsuit alleges that Eli Lilly, Novo Nordisk and Sanofi, as well as CVS Caremark, Express Scripts and OptumRx, overcharged diabetes patients in the state who require insulin. 

The three pharmaceutical companies supply more than 90 percent of the world’s insulin, and the three PBMs “administer pharmacy benefits for roughly 80% of prescription claims managed,” according to a news release from the attorney general’s office. 

With the suit, Attorney General Rob Bonta seeks a $2,500 civil penalty from the companies for every violation of the Business and Professions Code outlined in the suit.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.